Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
20.06. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.233 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
12.06. | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 362 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
22.05. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 4.822 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
15.05. | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 501 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen | |
10.04. | Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B | 7 | Seeking Alpha | ||
10.04. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | 1.367 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
07.03. | Relief Therapeutics and Renexxion terminate merger talks | 4 | Pharmaceutical Business Review | ||
06.03. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion | 6.352 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06-March-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
11.02. | Relief Therapeutics to get European patent for investigational drug RLF-TD011 | 19 | Seeking Alpha | ||
11.02. | Relief Therapeutics Holding SA: Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 | 652 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
22.01. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US | 4.277 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
22-Jan-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
27.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Provides Update on Potential Transaction with Renexxion | 798 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Merger
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27.12.2024 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
16.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial | 545 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Study results
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16.12.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
13.12.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations | 10.616 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13-Dec-2024 / 23:00 CET/CEST
Release... ► Artikel lesen | |
11.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.997 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11-Nov-2024 / 07:00... ► Artikel lesen | |
04.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger | 3.042 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04-Nov-2024 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
29.10.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE | 512 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
25.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents | 4.742 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25-Oct-2024 / 07:00 CET/CEST
Release... ► Artikel lesen | |
21.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment | 3.181 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21-Oct-2024... ► Artikel lesen | |
08.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.526 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
08-Oct-2024... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
REVIVE THERAPEUTICS | 0,016 | +82,35 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
QIAGEN | 41,550 | +1,43 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 15,480 | +0,32 % | Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% | ||
EVOTEC | 7,412 | +1,73 % | Evotec-Aktie: 5 Euro oder 10 Euro? Das sollten Anleger jetzt wissen! | © Foto: Bild von Rudolfs Klintsons auf PexelsDie Evotec-Aktie stürzt ab, während der Biotech-Sektor brummt. Der einstige Star aus Hamburg lieferte schwache Zahlen, verunsichert Anleger und sorgt mit... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 27,610 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
BIONTECH | 95,90 | -0,78 % | Wie BioNTech, PanGenomic Health und Pfizer mit Künstlicher Intelligenz Kosten sparen und ihre Rendite boosten | Die Digitalisierung revolutioniert die Biotechnologie- und Pharmabranche. Künstliche Intelligenz durchforstet Milliarden medizinischer Daten in Echtzeit und beschleunigt die Medikamentenentwicklung... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,510 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
LENZ THERAPEUTICS | 34,570 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,010 | +1,49 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
CUREVAC | 4,638 | -0,98 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
COGENT BIOSCIENCES | 12,220 | +3,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
ADMA BIOLOGICS | 17,590 | -0,45 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
WINDTREE THERAPEUTICS | 1,020 | 0,00 % | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,440 | +1,84 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
VERVE THERAPEUTICS | 10,955 | -0,41 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |